Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy-Reference-Cited by-同舟云学术

Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy

Published:2014-02 Issue:2 Volume:25 Page:173-176
ISSN:0953-6205
Container-title:European Journal of Internal Medicine
language:en
Short-container-title:European Journal of Internal Medicine

Author:

Mavrakanas Thomas A.,Gariani Karim,Martin Pierre-Yves

Publisher

Elsevier BV

Subject

Internal Medicine

Reference24 articles.

1. “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin-converting enzyme inhibitor: implications for therapy;Pitt;Cardiovasc Drugs Ther,1995

2. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats;Han;J Am Soc Nephrol,2006

3. Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats;Taira;Eur J Pharmacol,2008

4. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats;Fujisawa;Kidney Int,2004

5. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus;Guo;Endocrinology,2006

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic approaches and novel antifibrotic agents in renal fibrosis: A comprehensive review;Journal of Biochemical and Molecular Toxicology;2024-08

2. Leptin in reproduction and hypertension in pregnancy;Reproduction, Fertility and Development;2024-07-22

3. Hyperkalemia Incidence in Patients With Non-Dialysis Chronic Kidney Disease: A Large Retrospective Cohort Study From United States Clinical Care;Kidney Medicine;2024-07

4. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials;Frontiers in Medicine;2024-06-14

5. Alport Syndrome;Advances in Kidney Disease and Health;2024-05